文献速递肿瘤 PET/CT核素与放射性配体治疗

[68Ga]Ga-BP-IDA肝胆PET的临床前评估及其在肝功能监测中的转化潜力

Hepatobiliary PET with [68Ga]Ga-BP-IDA - preclinical evaluation and its translational potential for liver function monitoring.
PubMed 文献 · EJNMMI Res · 2025-10-02

本研究通过临床前实验探究[68Ga]Ga-BP-IDA的体内分布与分子通路,并在肝细胞癌TARE治疗病例中评估其定量监测肝功能的临床适用性。结果显示该探针经OATP1B1/1B3进入肝细胞并肝胆清除,虽存在体内脱金属但仍适用于临床;TARE后PET/CT可区分功能性肝组织与肿瘤,并显示非癌肝叶摄取率下降,右叶更显著,提示与更高非靶辐射剂量相关,提供CT体积测量之外的功能信息。

要点

  • [68Ga]Ga-BP-IDA经OATP1B1/1B3进入肝细胞并肝胆清除,适用于临床肝功能显像。
  • TARE后PET/CT可区分功能性肝组织与肿瘤,并监测肝/肿瘤体积及残余肝功能变化。
  • TARE后非癌肝叶摄取率下降,右叶更显著,提示与更高非靶辐射剂量相关。

核心结论

  • [68Ga]Ga-BP-IDA PET/CT适用于原发性肝肿瘤TARE治疗的规划与监测,并可以肝功能信息补充体积测量方法的局限。

研究设计与样本

  • 临床前研究评估[68Ga]Ga-BP-IDA的体内分布与分子通路,并在肝细胞癌TARE治疗病例中评估临床适用性。

主要发现

  • [68Ga]Ga-BP-IDA经OATP1B1和OATP1B3进入肝细胞并发生肝胆清除。
  • [68Ga]Ga-BP-IDA在体内存在脱金属,但因快速被功能性肝组织摄取而仍适合临床应用。
  • 临床病例中[68Ga]Ga-BP-IDA PET/CT可区分功能性肝组织与癌组织,并监测TARE后肝与肿瘤体积及残余肝功能变化。
  • TARE后两个非癌肝叶的肝脏摄取率均下降,右叶更显著,提示与该叶更高非靶辐射剂量相关。
  • [68Ga]Ga-BP-IDA PET/CT揭示了CT体积测量未能反映的肝功能受损额外信息。

临床怎么用

  • 可用于原发性肝肿瘤TARE治疗的规划与监测,并以肝功能信息弥补体积测量方法的不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of this study was to investigate the preclinical biodistribution and molecular pathway of [68Ga]Ga-BP-IDA and to evaluate its clinical suitability for quantitative monitoring of liver function during transarterial radioembolization (TARE) therapy of a hepatocellular carcinoma (HCC). RESULTS: [68Ga]Ga-BP-IDA undergoes hepatobiliary clearance, with uptake into hepatocytes via OATP1B1 and OATP1B3. [68Ga]Ga-BP-IDA exhibits demetallation in vivo but is nevertheless suitable for clinical application due to its rapid uptake into functional liver tissue. In a clinical case [68Ga]Ga-BP-IDA PET/CT allowed for differentiation of functional liver mass from cancerous tissue and enabled monitoring the effect on liver and tumor volume as well as on residual liver function after TARE therapy. Following TARE treatment, a reduction of the hepatic uptake rate was observed in both non-cancerous liver lobes, but was more pronounced in the right lobe, indicating a correlation to the higher non-targeted radiation dose from the TARE treatment in this lobe. [68Ga]Ga-BP-IDA PET/CT thus revealed additional information on liver function impairment which was not represented by CT-based volumetry alone. CONCLUSION: [68Ga]Ga-BP-IDA PET/CT is a suitable tool for planning and monitoring TARE therapy of primary liver tumors and may complement the limits of volumetry-based methods with functional information about the liver.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Greiser J, Drescher R, Pomraenke M, et al. Hepatobiliary PET with [68Ga]Ga-BP-IDA - preclinical evaluation and its translational potential for liver function monitoring. EJNMMI Res. 2025. PMID: 41039075. doi:10.1186/s13550-025-01327-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。